Inspire Medical Systems, Inc. · NYSE:INSP
Inspire Medical Systems — JP Morgan Healthcare Conference 2025
25 slides from Inspire Medical Systems's conference presentation, Jan 13, 2025
Slide 1: JP Morgan Healthcare Conference
© 2024 Inspire Medical Systems, Inc. All Rights Reserved Inspire Medical Systems, Inc. JP Morgan Healthcare Conference INSPIRE CONFIDENTIAL. Inspire is a public company and has an Insider Trading Policy. The content in this deck is not to be shared with anybody outside of Inspire Medical Systems, In
Slide 2: Disclaimer
JP Morgan Investor Update Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-look
Slide 3: Enhancing patient lives through sleep innovation
enhancing patient lives through sleep innovation I t a l l s tarts and ends wi th our mission We are a medical technology company committed to JP Morgan Investor Update
Slide 4: Over 17 years enhancing the lives of patients
From our entrepreneurial beginnings, and with a focus on delivering life-changing outcomes, we’ve been enhancing the lives of patients for over 17 years… >90,000 Patients treated >$800M Revenue >1,500 Implanters Founded 2007 IPO 2018 Today 4,000 Patients treated $50M Revenue 200 Implanters With new
Slide 5: Our global impact continues to climb
- 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 100,000 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Total implants New implants Minutes between implants Our global impact continues to climb >90K Patients treated with Inspire therapy to date A patient receives Inspire ther
Slide 6: Highlights in the quarter and full-year 2024: Sustained Rapid Growth
Highl ights in 4 th quarter and fu l l -year 2024 Sustained Rapid Growth JP Morgan Investor Update $51 $82 $115 $233 $408 $625 ~$803 2018 2019 2020 2021 2022 2023 2024 • Activated 72 new U.S. centers in Q4, bringing the total to 1,435 U.S. centers • Created 12 new U.S. sales territories in Q4, bring
Slide 7: Obstructive Sleep Apnea is caused by blockage that prevents airflow to the lungs
Obstructive Sleep Apnea is caused by blockage that prevents airflow to the lungs 7 Airway obstruction during breathing Typical OSA event • Results in repeated arousals and oxygen desaturations • Severity of sleep apnea is measured by frequency of apnea or hypopnea events per hour, which is referred
Slide 8: OSA is a chronic disease that is often untreated and linked to serious health risks
OSA is a chronic disease that is often untreated and proven to be linked to serious health risks 8 Exacerbated Health Risks • High risk patients: obese, male or of advanced age • Common first indicator: heavy snoring • Other indicators: • Lack of energy • Headaches • Depression • Nighttime gasping •
Slide 9: Current treatment options, such as CPAP and invasive surgeries, have significant limitations
Current treatment options, such as CPAP and invasive surgeries, have significant limitations 9 InaUvulopalatopharyngoplasty (UPPP) Maxillomandibular Advancement (MMA) • Several variations of sleep surgery • Success rates vary widely (30% - 60%)1 • Irreversible anatomy alteration • Inpatient surgery
Slide 10: The domestic OSA market is very large
JP Morgan Investor Update CPAP prescriptions annually ≈ 2,000,000 CPAP non-compliant ≈ 700,000 Inspire eligible ≈ 500,000 Adults with moderate to severe OSA ≈23,000,000 >$10B opportuni ty The domestic OSA market is very large…
Slide 11: Inspire Therapy is an Innovative and Proven Solution for Patients with OSA
Inspire Therapy is an Innovative and Proven Solution for Patients with OSA Inspire Therapy Utilizes a Proprietary Closed-Loop Sensing Algorithm to Modulate Therapy Delivery Inspire Solution 2 Typically a 60-90 min. outpatient procedure Requires only two small incisions Patients usually recover
Slide 12: Original Inspire Products – Inspire I and Inspire II
JP Morgan Investor Update Original Inspire Products – Inspire I and Inspire II 2005-20171995-2000 ®
Slide 13: Continuous Evolution of Inspire Therapy and Technology
Continuous Evolution of Inspire Therapy and Technology Silicone Leads: Q3 2022 Inspire IV: Q2 2017 Full Body MRI: Q3 2022 Redesigned Physician Programmer: Q1 2024 Inspire Cloud: 2017 SleepSync : Q1 2022 Inspire Remote: Q2 2016 Bluetooth® Remote: Q1 2022 Inspire V: 2025 • CE Mark Approval in Europe i
Slide 14: Inspire V Sensor Performance and Therapy Evolution
Current Sensor Inspire V Sensor Performance Therapy Evolution Built-in • Multiple electrodes capability • Enables new stim targets and sensing features Flexible Software Platform • Downloadable features for clinical studies and field upgrades • Future features could include posture-responsive therap
Slide 15: Initial Inspire V System experience with implants in Singapore and the U.S.
• Initial Experience in Singapore at the Singapore General Hospital • Professor Toh Song Tar • Dr. Shaun Loh Ray Han National University Hospital • Dr. Crystal Cheong • 40 of a planned 44 implants successfully completed to date • Strong feedback from physicians regarding improved procedure without h
Slide 16: SleepSync Digital Health Platform
Dynamic patient engagement + Efficient care coordination Expanding sleep clinician confidence & capacity enabling more patients to benefit from Inspire therapy Remote patient management Patient Inspire App Clinician SleepSync Web Portal • Find a doctor • Customized education • Track therapy & sleep
Slide 17: Strong Patient Outcomes
How does Inspire compare against your previous experience with CPAP? 91% Say Inspire is better I would recommend Inspire to a friend or family member. 93% Agree or strongly agree Overall, how satisfied are you with Inspire? 90% Satisfied or very satisfied Given the chance, I would choose to receive
Slide 18: Proven Safety
JP Morgan Investor Update Proven Safety Cons i s tent improvement in dev ice su rv ivabi l i ty year a f te r yearStrong Patient Outcomes Months after implant C um ul at iv e Im pl an t s ur vi va l Data on file • Inspire is committed to continually improving patient safety • Significant progress si
Slide 19: ...and we are just getting started!!
…and we are just getting started!! Continued scaling of the organization provides opportunity to align and focus our management team for continued growth • Chief Strategy and Growth Officer – Carlton Weatherby • Chief Manufacturing and Quality Officer – Jason Kelly • EVP, Patient Access and Therapy
Slide 20: Inspire V: On track for full launch in 2025
Inspire V On track for full launch in 2025 JP Morgan Investor Update
Slide 21: Delivering profitable growth
Del iver ing prof i tab le g rowth Continuing to invest in top line growth while improving profitability
Slide 22: First Mover. Market Disruptor. Innovation Leader.
First Mover. Market Disruptor. Innovation Leader. >90K pat ient s w i th Insp i re Proving out our care pathways and therapy optimization Cl in ica l ev idence t rove >300 publications boasting a compelling body of evidence >$800M revenue in 2024 28% year-over-year growth, continuing our strong perf
Slide 23: Inspire Medical Systems, Inc. mission and values
Inspire Medical Systems, Inc. We are a medical technology company committed to enhancing patient lives through sleep innovation “Put the pat ient f i r s t and you wi l l never lose your way.” Demonstrate Operational Excellence Drive Therapy Adoption Strengthen Organizational Culture Focused on Outc
Slide 24: Sustainability at Inspire
Sustainability at Inspire Committed to improving the economic, social, and environmental impacts that our business has on the communities in which we operate, as well as our customers, business partners, suppliers, employees, and stockholders. E N V I R O N M E N T A L We work to operate our busines
Slide 25: No mask. No hose. Just sleep.
No mask. No hose. Just sleep. INSPIRE CONFIDENTIAL. Inspire is a public company and has an Insider Trading Policy. The content in this deck is not to be shared with anybody outside of Inspire Medical Systems, Inc. It is for internal review and discussion only www.inspiresleep.com ®
Inspire Medical Systems — JP Morgan Healthcare Conference 2025 on 6ix